ReviewEye (London, England)2020
Advanced glaucoma at diagnosis: current perspectives.
Review in Eye (London, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 2 syntheses or guidelines pooled it, 74 citations in OpenAlex.
- National, regional, and provincial prevalence of glaucoma in China in 2020: an updated systematic review and modelling analysis.Journal of global health · 2025Pooled it
- Pooled it
- Genetic risk score to enhance glaucoma case detection: a prospective double-blind screening study (EyeLife) in the population-based Lifelines cohort.European journal of epidemiology · 2026Article
- Toward Long-Term Visual Field Appearance Forecasting Using Artificial Intelligence for Ophthalmic Education and Diagnosis.Ophthalmology science · 2026Article
- Sociodemographic and Clinical Determinants of Glaucoma in a Sub-Saharan African Population: A Case-Control Study.Health science reports · 2026Article
- Visual field progression in Asian glaucoma patients: a 10-year stratified cohort analysis from a national health system with universal coverage.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Article
- Factors Associated with Referral to Low Vision for Patients with Advanced Glaucoma.Life (Basel, Switzerland) · 2025Article
- Clinical Benefits of Preservative-Free Treatment for Glaucoma with a Focus on Preservative-Free Latanoprost.Ophthalmology and therapy · 2025Review
- Leveraging Alzheimer's Disease Omics to Identify Pleiotropic Genes Contributing to Neurodegeneration in Primary Open-Angle Glaucoma.Molecular neurobiology · 2025Article
- Visual and surgical outcomes of MMC augmented combined non-penetrating deep sclerectomy and phacoemulsification in eyes with severe and end stage glaucoma.Eye (London, England) · 2025Article
- Performance of Optic Disc Optical Coherence Tomography Normative Database in a Large, Diverse, Real-World Cohort.Journal of glaucoma · 2025Article
- Diagnostic accuracy of the TsiogkaSpaeth grid test for detecting visual field defects in patients with glaucoma.BMJ open ophthalmology · 2025Article
- Outcomes of Gonioscopy-Assisted Transluminal Trabeculotomy (GATT) in Advanced Glaucoma: A Retrospective Analysis.Medicina (Kaunas, Lithuania) · 2025Article
- Outcomes of non-penetrating deep sclerectomy combined with mitomycin C in advanced open-angle glaucoma in Indian eyes.Indian journal of ophthalmology · 2025Observational
- Efficacy and Safety of Cataract Surgery Combined with Ab Interno Canaloplasty and Micro-Trabecular Bypass Stent Surgery in Open-Angle Glaucoma.Clinical ophthalmology (Auckland, N.Z.) · 2025Article
- Review
- Primary Eyecare Glaucoma Service (PEGS): a mixed methods service evaluation.Eye (London, England) · 2024Article
- Associations of human blood metabolome with optic neurodegenerative diseases: a bi-directionally systematic mendelian randomization study.Lipids in health and disease · 2024Article
- MP-3 microperimeter in early primary open angle glaucoma with a new pattern.International journal of ophthalmology · 2024Article
- Measures of multiple deprivation and visual field loss in glaucoma clinics in England: lessons from big data.Eye (London, England) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Presentation with advanced glaucoma is a significant risk factor for lifetime blindness. The asymptomatic nature of glaucoma, particularly in early disease, means that substantial vision loss in one eye does not always translate into a perceptible loss of visual function. This, along with the lack of an effective screening strategy, contributes to late presentation. Those most at risk of presenting with advanced glaucoma have asymptomatic high intraocular pressure (IOP), no family history of glaucoma, are socially disadvantaged, and do not attend sight testing. Patients with glaucoma may have impaired functionality for daily activities, such as reading, walking and driving. Quality of life measures have shown this to be significantly worse in patients with more severe visual field loss, particularly if bilateral. In addition, quality of life decreases faster with further bilateral visual field loss when advanced visual field damage is present. Management of these patients requires disproportionally more resources than those with earlier disease. Both medical and surgical options are used as the initial approach to treat patients presenting with advanced glaucoma. The most recently published National Institute for Health and Care Excellence (NICE) guidelines suggest that patients presenting with advanced disease should be offered trabeculectomy as a primary intervention. However, more evidence is required to determine the best initial management. The Treatment of Advanced Glaucoma Study (TAGS) is being conducted, comparing primary medical management with primary mitomycin C-augmented trabeculectomy for people presenting with advanced open-angle glaucoma. The results of TAGS will provide robust evidence for the most appropriate initial intervention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.